Open opportunities (fellowships, awards, training, research, funding, career, etc.) of interest to NEALS members can be found here. Please contact Christina Smith, NEALS Communications Coordinator, at csmith@neals.org to submit an announcement for posting on the website.
We are hiring a postdoctoral researcher!
An exciting opportunity to join our new project on MRI-based imaging biomarker development in ALS. The appointment will be at the Center for Magnetic Resonance Research (CMRR) at the University of Minnesota. The CMRR is one of the world’s premier magnetic resonance imaging facilities, with considerable expertise in imaging physics, engineering, and clinical research. Further details and a formal application link are available at
https://hr.myu.umn.edu/jobs/ext/359206
CVs and/or informal inquiries about the position may be emailed to Pramod Pisharady at email hidden; JavaScript is required before submitting a formal application.
The ALS Association now accepting applications for The Hoffman ALS Clinical Trial Awards Program. This program provides up to $1,000,000 in total funding over two or three years to support early- to mid-stage (phase 1 or 2a) clinical trials of novel or repositioned therapeutics for ALS (either disease-modifying or symptomatic). Early trials testing imaging tracers in people living with ALS are also in scope.
Please note:
Letters of intent are due November 26, 2024, by 1 p.m. US ET. Click here for application instructions. If you have any questions, please email email hidden; JavaScript is required.
The Department of Neurology at Massachusetts General Hospital is recruiting a board certified or board-eligible Neurologist at the level of Instructor, Assistant Professor, or Associate Professor to join the Sean M. Healey & AMG Center for ALS and will be an integral part of the ALS multidisciplinary care team and a clinical trialist as part of the Neurological Clinical Research Institute based within in the Department.
Qualified applicants should have advanced training in Neuromuscular Medicine and clinical research experience as evidenced by field work, peer-reviewed publications, and grant-supported activities. Applicants should have a completed a neurology residency in a major teaching hospital and should be familiar with working with neurology residents, interns and fellows within an academic neurology department in a general hospital setting. This position will be based at MGH. An appointment at the Harvard Medical School along with a corresponding hospital appointment will be commensurate with experience, training, and achievements. In addition, it is expected that the candidate will engage in teaching in the Harvard community with a minimum of 50 hours required per year. Women and minority applicants are strongly encouraged to apply.
Interested candidates should submit a c.v. and cover letter to:
James Berry, MD, Division Chief, ALS and Motor Neuron Diseases via email at email hidden; JavaScript is required
The Centers for Disease Control/Agency for Toxic Substances and Disease Registry (CDC/ATSDR) is offering a grant opportunity for investigator-initiated research on potential risk factors contributing to Amyotrophic Lateral Sclerosis (ALS). The focus is on identifying and evaluating risk factors, with an emphasis on areas such as military service, contact sports, traumatic brain injury, neuroinflammation, and infectious agents.
The funding is structured into three options:
The total program funding is estimated at $7.5 million, with individual awards ranging from $0 to a maximum of $500,000. The closing date for applications is November 4, 2024, at 11:59 pm ET, and the project must be submitted electronically. For more information visit https://www.grants.gov/search-...
Contact: Candis M. Hunter, PhD, MSPH, REHS at email hidden; JavaScript is required.
The Harvard/Partners Neurodegeneration Clinical Research (NCR) Fellowship is designed to produce experts in the field of neurodegenerative diseases and clinical research, with a particular focus on the clinical care and research of neurodegenerative disease, who will shape clinical research in these fields throughout their career.
The Neurodegeneration Clinical Research Fellowship training will occur via two major avenues: 1) Clinical Care training conducted primarily through mentored clinical encounters and supplemented by clinical conferences and individual study; and 2) Clinical Research training conducted through the experience of acting as a sub-investigator on at least one non-interventional research project and at least one treatment trial, as well as the development of one unique clinical research project with the careful support of a research mentor.
Eligibility/Application Process
Candidates must be board-eligible in Neurology, have completed residency in good standing prior to the start of the fellowship, and have a strong interest in clinical research. Candidates may have completed a one year neuromuscular fellowship or equivalent prior to joining this fellowship.
For more information on the Neurodegenerative Clinical Research Fellowship, and how to apply, please view the fellowship website (https://www.mgbneurologyfellowships.org/fellowships/neurodegenerative.htmlcontact) and contact Program Director, email hidden; JavaScript is required.
The National Institute of Neurological Disorders and Stroke (NINDS) has recently re-issued a funding opportunity: “Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required), ” RFA-NS-24-029.
This funding opportunity is intended to support scientific research utilizing data from expanded access (EA) studies for ALS using investigational drugs or biological products. Eligible applicants must be clinical trial sites that participate in a phase 3/efficacy clinical trial supported by a small business concern that is the FDA-designated sponsor of a drug or biological product which is the subject of an IND under section 505(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(i)) to prevent, diagnose, mitigate, treat, or cure ALS. The definition of a small business concern can be found at https://seed.nih.gov/small-business-funding/small-business-program-basics/eligibility-criteria.
NINDS encourages eligible drug sponsors to review RFA-NS-24-029 and consider working with an eligible Phase 3 clinical trial site to submit an application.
NINDS program staff (contact information below) are available to address any questions you may have about the funding opportunity, and to discuss your application should you choose to submit. For more information about technical assistance webinars for potential applicants, see the Notice Number NOT-NS-24-036 for additional information, including registration guidance: https://grants.nih.gov/grants/guide/notice-files/NOT-NS-24-036.html
Amy Tsou, Program Director, Division of Clinical Research, NINDS, email hidden; JavaScript is required
Emily Caporello, Program Director, Division of Translational Research, NINDS, email hidden; JavaScript is required
Amelie Gubitz, Program Director, Division of Neuroscience, NINDS, email hidden; JavaScript is required
Lumy Sawaki-Adams, Program Director, Division of Clinical Research, NINDS, email hidden; JavaScript is required
The National Institute of Neurological Disorders and Stroke (NINDS) has recently re-issued a funding opportunity: “Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required), ” RFA-NS-25-024.
This funding opportunity is intended to support scientific research utilizing data from expanded access (EA) studies for ALS using investigational drugs or biological products. Eligible applicants must be clinical trial sites that participate in a phase 3/efficacy clinical trial supported by a small business concern that is the FDA-designated sponsor of a drug or biological product which is the subject of an IND under section 505(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(i)) to prevent, diagnose, mitigate, treat, or cure ALS. The definition of a small business concern can be found at https://seed.nih.gov/small-business-funding/small-business-program-basics/eligibility-criteria.
NINDS encourages eligible drug sponsors to review RFA-NS-25-024 and consider working with an eligible Phase 3 clinical trial site to submit an application.
NINDS program staff (contact information below) are available to address any questions you may have about the funding opportunity, and to discuss your application should you choose to submit. In addition, technical assistance webinars for potential applicants to RFA-NS-25-024 will be scheduled prior to the submission due date.
Amy Tsou, Program Director, Division of Clinical Research, NINDS, email hidden; JavaScript is required
Emily Caporello, Program Director, Division of Translational Research, NINDS, email hidden; JavaScript is required
Amelie Gubitz, Program Director, Division of Neuroscience, NINDS, email hidden; JavaScript is required
Dina Lyon, Clinical Research Project Manager, Division of Clinical Research, email hidden; JavaScript is required
MDA provides support for research throughout the pipeline of drug development from discovery research through clinical trials. Funding opportunities exist for both academic investigators as well as for biotech and pharma seeking to develop therapies for neuromuscular disease.
Learn about all our grant programs and find deadlines and instructions on how to apply.
The 5th annual Sean M. Healey International Prize for Innovation in ALS is a global prize celebrating excellence in research for a team of investigators who catalyze exceptional discoveries leading to a transformative advance in therapy development in ALS. Novel advances could include, but are not limited to, technologies, tools or targets that lead to new insight, drug development, or clinical trial improvement.
Nominations Due: Friday, July 26th at 5pm EST
Presentation of award: International Symposium on ALS/MND December 6-8, 2024
Award: $50,000 USD and travel reimbursement up to $2,500 USD to attend International Symposium on ALS/MND
To learn more about the 6th annual prize and how to nominate a team, click here.
The Association for Frontotemporal Degeneration (AFTD), in collaboration with the Alzheimer's Drug Discovery Foundation (ADDF), invites submissions for early-stage clinical trials under the Treat FTD Fund.
The Treat FTD Fund seeks to support clinical trials incorporating:
Award Details:
Up to $2,500,000 based on stage and scope of the trial. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged. Payment structure will be negotiated and based on milestone achievements and patient enrollment.
Who Can Apply?
Researchers and clinicians worldwide at:
Deadlines:
Applications will be reviewed confidentially by a panel of FTD experts. Applicants may expect to receive recommended revisions to their workplan or clinical trial design as part of the review process. Click here to view the RFP and access the application portal.
For more details, click here.
The Drs. Ayeez and Shelena Lalji & Family ALS Endowed Award for Innovative Healing is a global award celebrating excellence in research for an individual or team of investigators who are making transformative breakthroughs in the science of repair and regeneration of neurological function. Our goal is to identify and recognize therapies and modalities to regain loss of neural function in ALS or that may be applied in ALS patients in the future.
Award Criteria:
The Lalji Family ALS Award is accepting nominations for individual or team of investigators who have made significant progress impacting the repair and regeneration of neuronal degeneration that may be applied in ALS. Examples include but are not limited to:
Nominations Due: Friday, August 23rd at 5pm EST
Presentation of award: International Symposium on ALS/MND December 6-8, 2024
Award: $40,000 USD and travel reimbursement up to $2,500 USD to attend International Symposium on ALS/MND
To learn more about the annual Lalji Family award and how to nominate an individual or team, click here.